secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2022-09-06T23:59:59+00:00
Accession:  0001193125-22-238857
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal appoints Gustavo Pesquin as EVP, Chief Commercial Officer – Specialty
----------------------------------------------------------------------------

- Pesquin joins from Sanofi, where he was North America Head for General Medicines.
- Base salary $525,000; target annual bonus 60% of base salary; RSU grant of $1,000,000 vesting over 4 years.
- Severance: 150% of base salary plus pro-rata bonus and 18 months benefits if terminated without cause or for good reason.
- Effective September 6, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000119312522238857/0001193125-22-238857-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000119312522238857/d385461d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-238857

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer